1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Procyon Corporation

Procyon Corporation

PCYN
Procyon CorporationUS flagOther OTC
0.20
USD
- -
- -
1.63MMarket Cap
Procyon Corporation
PCYN
(Other OTC)

Recent

price

0.20

P/E

ratio

- -

div

yld

- -

ROIC.AI

2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
TTM
FRC
0.29
0.32
0.34
0.35
0.34
0.35
0.34
0.43
0.5
0.5
0.52
0.54
0.58
0.6
0.58
- -
0.61
Revenue per Share
- -
0.01
0.02
0.01
-0.02
- -
-0.03
0.01
- -
-0.03
- -
0.01
0.08
-0.03
-0.01
- -
-0.04
Basic EPS, GAAP
0.02
0.03
0.01
0.05
- -
-0.02
-0.06
-0.01
0.02
- -
- -
0.02
0.03
-0.06
- -
- -
-0.02
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.32
-0.3
-0.28
-0.26
-0.28
-0.27
0.25
0.26
0.26
0.23
0.24
0.25
0.34
0.31
0.3
- -
0.26
Book Value per Share
0.23
0.25
0.27
0.29
0.27
0.28
0.25
0.26
0.26
0.23
0.24
0.25
0.34
0.31
0.31
- -
0.27
Tangible Book Value per Share
8
8
8
8
8
8
8
8
8
8
8
8
8
8
8
- -
8
Basic Weighted Avg Shares
2
3
3
3
3
3
3
3
4
4
4
4
5
5
5
5
5
Sales/Revenue/Turnover
6.79
7.15
12.4
8.26
-0.46
2.3
-12.32
-3
0.75
3.16
2.32
3.53
4.8
-4.9
-2.08
-4.65
-4.65
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
- -
- -
- -
- -
Net Income, GAAP
39.05
37.53
37.97
40.82
- -
65.75
- -
42.38
57.3
300.35
72.59
30.24
5.38
- -
- -
- -
- -
Effective Tax Rate (%)
1.04
4.82
7.14
4.59
-3.79
0.83
-7.87
3.18
0.31
-6.36
0.65
2.58
14.71
-4.33
-1.07
-6.84
-6.84
Profit Margin (%)
1
1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
2
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
- -
- -
- -
- -
LT Debt
2
2
2
2
2
2
2
2
2
2
2
2
3
3
3
2
2
Total Equity
3.99
4.54
7.95
5.23
- -
0.95
- -
-2.58
0.55
-11.78
1.3
4.84
7.11
- -
- -
- -
- -
Return on Invested Capital (%)
-2.3
-7.46
-11.62
-7.65
- -
-1.14
- -
4.85
0.58
-11.91
1.34
5.08
23.22
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
4.39
1.21
-13.62
0.54
4.82
28.61
-8.68
-2.7
-13.65
-13.65
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'24
Jun'24
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
8
8
8
Market Capitalization
1
2
2

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'24
Jun'24
Total Current Assets
2
2
2
Cash, Cash Equivalents & STI
1
1
1
Accounts Receivable, Net
1
- -
1
Inventories
1
1
1
Total Current Liabilities
1
1
1
Payables & Accruals
- -
1
1
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
0.33%
3.26%
-12.62%
Free Cash Flow
10.19%
113.73%
260.99%
Net Income, GAAP
-233.54%
240.94%
578.95%
Sales/Revenue/Turnover
6.09%
3.61%
6.35%
Total Cash Common Dividend
- -
- -
-268.63%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
1
1
1
1
5
2023
1
1
1
1
5
2024
1
1
1
1
5

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
-0.01
-0.01
- -
-0.03
2023
- -
- -
- -
- -
-0.01
2024
- -
-0.03
-0.01
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
Similar Companies
Canntab Therapeutics Limited (PILL.CN)
Althea Group Holdings Limited (AGH.AX)
Amneal Pharmaceuticals, Inc. (AMRX)
Boryung Corporation (003850.KS)
Generation Hemp, Inc. (GENH)
PolyPeptide Group AG (0AAJ.L)
Business
Procyon Corporation (Ticker: PCYN) develops and commercializes innovative technologies for the biotechnology and life sciences sectors. The company offers a portfolio of core products and services including proprietary diagnostic assays for early disease detection; advanced molecular imaging platforms; custom contract research services for pharmaceutical clients; and AI-driven data analytics tools for genomic sequencing, all designed to accelerate drug discovery and personalized medicine. Procyon operates primarily in North America and Europe, targeting pharmaceutical companies, research institutions, and clinical laboratories as key customers. Founded in 2012 and headquartered in San Diego, California, the company maintains strategic subsidiaries focused on regulatory compliance and international distribution. In the past year, Procyon announced a major strategic alliance with a leading global pharmaceutical firm to co-develop next-generation cancer therapeutics; completed a $75 million Series C funding round led by prominent venture capital investors to fuel expansion into Asia-Pacific markets; and launched its flagship ProcyonGenix AI platform, marking a shift toward integrated digital health solutions.